Aminergic pharmaceutical compositions and methods

The pharmaceutical composition according to claim 277, wherein said complement is EDTA.

The pharmaceutical composition according to claim 274, wherein said complement comprises an opioid.

The pharmaceutical composition according to claim 274, wherein said complement comprises a resveratrol family member.

The pharmaceutical composition according to claim 274, wherein said complement comprises a cysteine family member.

The pharmaceutical composition according to claim 274, wherein said composition is suitable for oral administration.

The pharmaceutical composition according to claim 274, wherein said composition is suitable for topical administration.

The composition according to claim 273, wherein said non-adrenergic aminergic compound is a dopaminergic compound selected from the group consisting of quinpirole, carmoxirole, 2-amino-5,6-dihydroxy-1,2,3,4-tetrahydronaphthalene, lisuride, pergolide, apomorphine, haloperidol, domperidone, metaclopramide, spiperone, haloperidol, diphenylbutylpiperidine, ecopipam, fenoldopam, fluphenazine, flupentixol, sulpiride, phenothiazines, thioxanthenes, naloxone, bromocriptine, substituted dopamine derivatives;

• pharmaceutically acceptable salts or esters thereof;
• and combinations thereof.

The composition according to claim 273, wherein said non-adrenergic aminergic compound is a histaminergic compound selected from the group consisting of 2-(2-pyridyl)ethylamine, histaprodifen (2-[2-(3,3-diphenylpropyl)-1H-imidazol-4-yl]ethylamine), N-methyl-histaprodifen, N-alpha-2-[(1H-imidazol-4-yl)ethyl]histaprodifen, (6-[2-(4-imidazolyl)ethylamino]-N-(4-trifluoromethylphenyl)heptanecarboxamide), dexchlorpheniramine, diphenhydramine;

• amthamine, clozapine, clobenpropit, dimaprit, imetit, immepip, impromidine, (+)-chlorpheniramine, cimetidine, ciproxifan, clobenpropit, pyrilamine, mepyramine, ranitidine, terfenadine, thioperamide, tiotidine, triprolidine, substituted histamine derivatives;
• pharmaceutically acceptable salts or esters thereof;
• and combinations thereof.

The composition according to claim 273, wherein said non-adrenergic aminergic compound is a muscarinergic compound, selected from the group consisting of aceclidine, arecoline, atropine, benzhexyl, benztropine, cevimeline, 2-ethyl-8-methyl-2,8-diazaspiro(4.5)decane-1,3-dione, R-(Z)-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile, milameline, oxotremorine, pilocarpine, pirenzepine, scopolamine, talsaclidine, telenzepine, trihexyphenidyl, xanomeline, substituted acetylcholine derivatives;

• pharmaceutically acceptable salts or esters thereof;
• and combinations thereof.

The method according to claim 273, wherein said non-adrenergic aminergic compound is a serotoninergic compound, selected from the group consisting of amphetamines, ergotamine, lysergate derivatives, almotriptan, buspirone, chlorpromazine, clozapine, cisapride, cyanopindolol, cyproheptadine, dexfenfluramine, dextromethorphan, dolasetron, donitriptan, eletriptan, eltoprazine, fenfluramine, fluoxetine, fluvoxamine, gepirone, granisetron, ketanserin, loxapine, meperidine, mesulergine, methiothepin, metergoline, methysergide, metoclopramide, mianserin, naratriptan, 1-naphthylpiperazine, nefazodone, olanzapine, ondansetron, paroxetine, pindolol, propranolol, risperidone, ritanserin, rizatriptan, spiperone, sertraline, sumatriptan, tropisetron, zolmitriptan, 8-hydroxy-dipropylaminotetralin, 2-(2-methyl-4-chlorophenoxy)propanoic acid, substituted 5-hydroxy-tryptamine derivatives;

• pharmaceutically acceptable salts or esters thereof;
• and combinations thereof.

A pharmaceutical composition comprising:

• (a) a subefficacious amount of an aminergic compound;
• and
• (b) a safe and effective amount of a complement compound that is any of the resveratrol family members or cysteine family members.

A method for treating a disorder associated with a non-adrenergic biogenic amine receptor in a human or animal subject, comprising:

• (a) administering to said subject a low dose of a non-adrenergic aminergic compound;
• and
• (b) administering to said subject a safe and effective amount of a complement compound.

A pharmaceutical composition comprising:

• (a) a subefficacious amount of an adrenergic antagonist compound;
• and
• (b) a safe and effective amount of a complement compound.